vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Ladder Capital Corp (LADR). Click either name above to swap in a different company.
Ladder Capital Corp is the larger business by last-quarter revenue ($22.3M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). Ladder Capital Corp runs the higher net margin — 71.0% vs -0.8%, a 71.9% gap on every dollar of revenue. On growth, Ladder Capital Corp posted the faster year-over-year revenue change (-18.0% vs -25.7%). Ladder Capital Corp produced more free cash flow last quarter ($78.7M vs $-15.8M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -22.5%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Ladder Capital Corp is a leading commercial real estate finance firm operating primarily across the United States. It originates and manages a diversified portfolio of senior secured commercial mortgage loans, mezzanine debt, commercial mortgage-backed securities, and direct real estate assets, serving property owners, operators and developers across major market segments.
CTMX vs LADR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $22.3M |
| Net Profit | $-154.0K | $15.9M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 69.5% |
| Net Margin | -0.8% | 71.0% |
| Revenue YoY | -25.7% | -18.0% |
| Net Profit YoY | 97.6% | -49.4% |
| EPS (diluted) | — | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $22.3M | ||
| Q3 25 | — | $27.8M | ||
| Q2 25 | $18.7M | $21.5M | ||
| Q1 25 | $50.9M | $20.3M | ||
| Q4 24 | $38.1M | $27.2M | ||
| Q3 24 | $33.4M | $38.4M | ||
| Q2 24 | $25.1M | $34.3M | ||
| Q1 24 | $41.5M | $37.1M |
| Q4 25 | — | $15.9M | ||
| Q3 25 | — | $19.2M | ||
| Q2 25 | $-154.0K | $17.1M | ||
| Q1 25 | $23.5M | $11.6M | ||
| Q4 24 | $18.9M | $31.3M | ||
| Q3 24 | $5.7M | $27.6M | ||
| Q2 24 | $-6.5M | $32.1M | ||
| Q1 24 | $13.8M | $16.4M |
| Q4 25 | — | 69.5% | ||
| Q3 25 | — | 72.4% | ||
| Q2 25 | -6.9% | 96.7% | ||
| Q1 25 | 44.4% | 52.7% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | 74.1% | ||
| Q2 24 | -33.7% | 90.4% | ||
| Q1 24 | 28.1% | 49.4% |
| Q4 25 | — | 71.0% | ||
| Q3 25 | — | 69.0% | ||
| Q2 25 | -0.8% | 79.5% | ||
| Q1 25 | 46.2% | 56.8% | ||
| Q4 24 | 49.6% | 115.1% | ||
| Q3 24 | 17.2% | 71.7% | ||
| Q2 24 | -26.0% | 93.6% | ||
| Q1 24 | 33.3% | 44.2% |
| Q4 25 | — | $0.13 | ||
| Q3 25 | — | $0.15 | ||
| Q2 25 | — | $0.14 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | — | $0.22 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $38.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $1.5B |
| Total Assets | $175.1M | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $38.0M | ||
| Q3 25 | — | $49.4M | ||
| Q2 25 | $49.0M | $134.9M | ||
| Q1 25 | $47.6M | $479.8M | ||
| Q4 24 | $38.1M | $1.3B | ||
| Q3 24 | $40.6M | $1.6B | ||
| Q2 24 | $43.2M | $1.2B | ||
| Q1 24 | $36.2M | $1.2B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $119.9M | $1.5B | ||
| Q1 25 | $25.0M | $1.5B | ||
| Q4 24 | $-456.0K | $1.5B | ||
| Q3 24 | $-23.5M | $1.5B | ||
| Q2 24 | $-31.2M | $1.5B | ||
| Q1 24 | $-31.7M | $1.5B |
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.7B | ||
| Q2 25 | $175.1M | $4.5B | ||
| Q1 25 | $98.5M | $4.5B | ||
| Q4 24 | $120.5M | $4.8B | ||
| Q3 24 | $139.0M | $4.8B | ||
| Q2 24 | $159.2M | $4.8B | ||
| Q1 24 | $184.7M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $87.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $78.7M |
| FCF MarginFCF / Revenue | -84.6% | 352.4% |
| Capex IntensityCapex / Revenue | 0.1% | 37.4% |
| Cash ConversionOCF / Net Profit | — | 5.49× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $118.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $87.0M | ||
| Q3 25 | — | $26.3M | ||
| Q2 25 | $-15.8M | $44.0M | ||
| Q1 25 | $-21.0M | $-28.7M | ||
| Q4 24 | $-19.9M | $133.9M | ||
| Q3 24 | $-20.7M | $169.0M | ||
| Q2 24 | $-19.5M | $45.4M | ||
| Q1 24 | $-26.0M | $-20.4M |
| Q4 25 | — | $78.7M | ||
| Q3 25 | — | $25.9M | ||
| Q2 25 | $-15.8M | $43.4M | ||
| Q1 25 | $-21.2M | $-29.6M | ||
| Q4 24 | $-20.0M | $127.4M | ||
| Q3 24 | $-20.7M | $166.0M | ||
| Q2 24 | $-19.6M | $44.9M | ||
| Q1 24 | $-26.2M | $-21.7M |
| Q4 25 | — | 352.4% | ||
| Q3 25 | — | 93.1% | ||
| Q2 25 | -84.6% | 201.6% | ||
| Q1 25 | -41.6% | -145.6% | ||
| Q4 24 | -52.5% | 468.2% | ||
| Q3 24 | -62.1% | 432.1% | ||
| Q2 24 | -78.2% | 131.0% | ||
| Q1 24 | -63.1% | -58.6% |
| Q4 25 | — | 37.4% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 0.1% | 2.9% | ||
| Q1 25 | 0.2% | 4.3% | ||
| Q4 24 | 0.2% | 23.9% | ||
| Q3 24 | 0.1% | 7.8% | ||
| Q2 24 | 0.4% | 1.3% | ||
| Q1 24 | 0.3% | 3.7% |
| Q4 25 | — | 5.49× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 2.57× | ||
| Q1 25 | -0.89× | -2.49× | ||
| Q4 24 | -1.05× | 4.27× | ||
| Q3 24 | -3.61× | 6.13× | ||
| Q2 24 | — | 1.41× | ||
| Q1 24 | -1.89× | -1.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LADR
Segment breakdown not available.
